These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15757941)

  • 1. Medicaid policies to contain psychiatric drug costs.
    Koyanagi C; Forquer S; Alfano E
    Health Aff (Millwood); 2005; 24(2):536-44. PubMed ID: 15757941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical analysis of studies of state drug reimbursement policies: research in need of discipline.
    Soumerai SB; Ross-Degnan D; Fortess EE; Abelson J
    Milbank Q; 1993; 71(2):217-52. PubMed ID: 8510601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicaid's prior authorization program and access to atypical antipsychotic medications.
    Polinski JM; Wang PS; Fischer MA
    Health Aff (Millwood); 2007; 26(3):750-60. PubMed ID: 17485754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics: considerations for Medicaid coverage.
    Surles RC
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S248-53. PubMed ID: 16180963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill.
    Soumerai S
    J Clin Psychiatry; 2003; 64 Suppl 17():19-22. PubMed ID: 14680423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit.
    West JC; Wilk JE; Muszynski IL; Rae DS; Rubio-Stipec M; Alter CL; Narrow WE; Regier DA
    Am J Psychiatry; 2007 May; 164(5):789-96. PubMed ID: 17475738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid cost containment and access to prescription drugs.
    Cunningham PJ
    Health Aff (Millwood); 2005; 24(3):780-9. PubMed ID: 15886173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
    Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
    Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
    Law MR; Ross-Degnan D; Soumerai SB
    Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managed care's atypical response. New antipsychotics show promise, but are they getting into enough hands?
    Waldron T
    Behav Healthc Tomorrow; 1999 Apr; 8(2):28-31. PubMed ID: 10351297
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004.
    Sankaranarayanan J; Puumala SE
    Curr Med Res Opin; 2007 Jun; 23(6):1375-85. PubMed ID: 17594776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-cost use of second-generation antipsychotics under California's Medicaid program.
    Stahl SM; Grady MM
    Psychiatr Serv; 2006 Jan; 57(1):127-9. PubMed ID: 16399974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid prior authorization policies for pediatric use of antipsychotic medications.
    Schmid I; Burcu M; Zito JM
    JAMA; 2015 Mar; 313(9):966-8. PubMed ID: 25734740
    [No Abstract]   [Full Text] [Related]  

  • 19. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
    Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
    Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.